Drugs / Granisetron
Granisetron
also known as
granisetron hydrochloride · Sancuso · APF530 · AZ 010 · Granitryl · GTDS · Kytril · Staccato Granisetron · +23 more
Other / unclassified targets HTR3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Sancuso | — | 2012-04-20 | europa.eu ↗ |
| Label expansions (5) | US (FDA) | KYTRIL | — | 1997-01-21 – 2011-04-29 | fda.gov ↗ |
| Approved | US (FDA) | KYTRIL | — | 1993-12-29 | fda.gov ↗ |
Trials 52 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT01649258 | Sep 2012 → May 2017 | breast cancer | University of Southern California | Terminated | No outcome recorded |
| Phase 1 | NCT01596400 | May 2012 → Aug 2015 | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00890565 | May → Aug 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00873197 | Apr → May 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00868764 | Apr → Sep 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00511823 | Jul → Sep 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00834717 | Sep 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00834522 | Jul 2005 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01596413 | — | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT01596426 | — | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Withdrawn | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05325190 | Oct 2021 → Dec 2022 | chemotherapy-induced toxicity | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04645953 | Feb 2021 → Jul 2022 | cyclic vomiting syndrome | Alexza Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04472143 | Jul 2020 → Sep 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03924518 | Apr 2019 → Nov 2020 | infectious disease with sepsis | Zhujiang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04501211 | Jan 2019 → Dec 2020 | gastroparesis | Indiana University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02457195 | Feb 2016 → Feb 2018 | — | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01909856 | Oct 2011 → Apr 2014 | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01183481 | Jan 2011 → Mar 2013 | — | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded |
| Phase 2 | NCT00787566 | Oct 2008 → Apr 2009 | chemotherapy-induced toxicity | Shin Nippon Biomedical Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00503386 | Apr → Oct 2006 | — | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00450853 | Apr → Nov 2005 | — | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT01952886 | ? → Sep 2014 | malignant glioma | Duke University | Withdrawn | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT06281418 | Feb → Dec 2024 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 3 | NCT04912271 | Jun 2021 → Jun 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT05087615 | Mar → Aug 2021 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03817970 | Nov 2019 → Sep 2027 expected | cisplatin toxicity | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03483350 | Mar → Aug 2018 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT02106494 | Mar 2014 → May 2015 | chemotherapy-induced toxicity | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01937156 | Aug 2013 → Jan 2014 | chemotherapy-induced toxicity | Solasia Pharma K.K. | Completed | No outcome recorded |
| Phase 3 | NCT01989221 | Nov 2012 → Dec 2018 | gastroparesis | Temple University | Completed | No outcome recorded |
| Phase 3 | NCT01536392 | Mar 2012 → Oct 2019 | cervical cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00475085 | Dec 2006 → Dec 2012 | — | Joseph Roscoe | Completed | No outcome recorded |
| Phase 3 | NCT00343460 | Jun 2006 → Sep 2008 | cancer of unknown primary site | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00273468 | Jan → Oct 2006 | chemotherapy-induced toxicity | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00020657 | Jul 2001 → Oct 2004 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 3 | NCT00003213 | May 1996 → Apr 1999 | cancer of unknown primary site | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00005024 | — | cancer of unknown primary site | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 3 | NCT00004219 | — | testicular germ cell tumor | Simbec Research | Unknown | No outcome recorded |
| Phase 410 trials | ||||||
| Phase 4 | NCT07360431 | Mar 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07401745 | Jan → Jul 2026 overdue | temporomandibular joint disorder | Mansoura University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05434663 | Jul 2022 → Oct 2025 | chemotherapy-induced toxicity | Heron Therapeutics | Unknown | No outcome recorded |
| Phase 4 | NCT06454825 | Apr 2020 → Apr 2021 | disorder of facial skeleton | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 4 | NCT06043336 | May 2018 → May 2019 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 4 | NCT03503292 | May 2018 → Dec 2019 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01662687 | Feb → Oct 2012 | chemotherapy-induced toxicity | LG Life Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01659775 | Aug 2011 → Nov 2012 | chemotherapy-induced toxicity | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00231478 | Apr → Dec 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02230371 | Mar 2007 → Oct 2014 | myofascial pain syndrome, temporomandibular joint disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06175806 | Sep → Nov 2023 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT01843868 | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded |
| — | NCT01275664 | Jun 2011 → May 2014 | fallopian tube cancer, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +5 | Gynecologic Oncology Group | Terminated | No outcome recorded |
| — | NCT00502437 | — | — | Hadassah Medical Organization | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 53 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04290026 Comparator | Apr 2021 → Jan 2022 | aspiration pneumonia | Assiut University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT04200092 Comparator | Nov 2019 → Jan 2020 | — | Nova Pneuma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03333824 Background | Dec 2017 → Jan 2019 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02563951 Comparator | Sep → Dec 2015 | cancer | Maxinase Life Sciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01073696 Comparator | Mar → Apr 2010 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT06031090 Comparator | Mar → Oct 2023 | benign shuddering attacks | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT04570592 Comparator | Oct 2020 → Apr 2021 | — | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 2 | NCT04085393 Comparator | Aug 2020 | chemotherapy-induced toxicity | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 2 | NCT03483870 Comparator | Jun 2018 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02588547 Comparator | Nov 2015 → May 2017 | benign shuddering attacks | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00186628 Background | Jun 2005 → Nov 2010 | mantle cell lymphoma, mast cell leukemia | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00450801 Background | Apr 2004 → Jul 2015 | lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT00003817 Background | Oct 1999 → Jul 2001 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 2 | NCT00666783 Comparator | — | chemotherapy-induced toxicity | Xijing Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05314257 Comparator | Apr → Nov 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT05711823 Comparator | Jul → Dec 2024 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04918862 Comparator | Jan → May 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04437017 Comparator | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT04613726 Comparator | Dec 2018 → Dec 2019 | hypotensive disorder | Ataturk University | Completed | No outcome recorded |
| Phase 3 | NCT02116530 Background | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT01499849 Background | Feb 2012 → May 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01500213 Background | Feb 2012 → Mar 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01500226 Background | Feb 2012 → Feb 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00952341 Background | Aug 2009 → Apr 2010 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00359567 Comparator | Jul 2006 → May 2007 | chemotherapy-induced toxicity | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00272285 Comparator | Jan 2006 → Dec 2007 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT06540885 Comparator | Jan 2025 → Jul 2026 overdue | idiopathic scoliosis | University of Malaya | Recruiting | No outcome recorded |
| Phase 4 | NCT06513806 Comparator | Aug → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05632224 Comparator | Nov 2022 → Jan 2023 | — | Baskent University | Unknown | No outcome recorded |
| Phase 4 | NCT04899817 Comparator | May 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04817189 Comparator | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 4 | NCT04150614 Comparator | May 2020 → Jul 2026 overdue | chemotherapy-induced toxicity | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT03091881 Comparator | Mar → Sep 2018 | — | Suez Canal University | Completed | No outcome recorded |
| Phase 4 | NCT03180229 Comparator | May → Sep 2017 | cholelithiasis | Diskapi Yildirim Beyazit Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03017391 Comparator | Jan 2017 → Apr 2018 | cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02441894 Background | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01636947 Background | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01352130 Comparator | Mar → Apr 2007 | — | Tata Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00415103 Comparator | Nov 2006 → Sep 2009 | leukemia, lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT06502067 Background | Jul 2024 → Jun 2025 overdue | breast cancer | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT06437236 Comparator | Apr → Dec 2024 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT06762860 Comparator | Jan 2024 → Jan 2025 | benign shuddering attacks | Minia University | Unknown | No outcome recorded |
| — | NCT06778460 Background | May 2023 → Mar 2027 expected | chronic pain syndrome | West China Hospital | Recruiting | No outcome recorded |
| — | NCT05474001 Comparator | Jun 2022 → Aug 2023 | — | Mohamed Youssef Mohamed | Unknown | No outcome recorded |
| — | NCT06000137 Background | Feb 2022 → Jan 2023 | — | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT05230654 Background | Feb → Apr 2022 | chemotherapy-induced toxicity | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| — | NCT04873284 Background | May → Dec 2021 | chemotherapy-induced toxicity, childhood malignant neoplasm | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| — | NCT03434340 Background | Jun 2018 → Mar 2019 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT03956446 Background | Sep 2014 → Dec 2027 expected | tick-borne encephalitis | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT02463942 Background | Sep 2014 → Sep 2020 | tick-borne encephalitis | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT00293384 Background | Oct 2004 → Jun 2009 | breast cancer, gestational trophoblastic neoplasm, leukemia, myelodysplastic syndrome +5 | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-01-03 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Generic Kytril® Injection And Tablets tevapharm.com ↗ |
| 2005-08-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Granisetron Hydrochloride Injection tevapharm.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 108 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Granisetrón | “5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential...” NCT01843868 ↗100“The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 “APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV).” PMID 26997579 ↗ Mar 2016 “Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline).” NCT02463942 ↗ “Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.” NCT05230654 ↗ “SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV)” NCT05434663 ↗ “Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.” NCT06778460 ↗ “as compared to Granisetron IV Injection and Granisetron Tablet in healthy Volunteers.” NCT02563951 ↗ “Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy” NCT00415103 ↗ “Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV)” NCT01659775 ↗ “Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ “Patients in Group G received 3 mg granisetron (Neoset, Deva, Istanbul)” NCT06454825 ↗ “Granisetron (Granitryl 1 mg/ml, ampules, EGYPHARMA, Egypt)” NCT07401745 ↗ “Sancuso® (granisetron transdermal system) 3.1 mg/24 hours” NCT01989221 ↗ “Granisetron: 1 mg d1 intravenously, or 2 mg d1 orally” NCT04437017 ↗ “1 mg (1 mL) IV granisetron after spinal placement.” NCT05474001 ↗ “granisetron transdermal system” NCT01596413 ↗ “IV Granisetron 1mg” NCT04200092 ↗ “IV granisetron” NCT01596426 ↗ |
| Known as | APF530 | “AIM: APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV).” PMID 26997579 ↗ Mar 2016 |
| Known as | AZ 010 | “A single oral dose of 0.5 mg AZ-010 (Staccato Granisetron) administered to 8 subjects” NCT04200092 ↗1“Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ |
| Known as | Bema granisetron | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | BRL 43694 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | BRL 43694A | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | G Setron | “the effect of the antiemetic drug Granisetron (G Setron 1 mg in 1 ml ampule) in reducing the incidence of hypotension” NCT03091881 ↗ |
| Known as | GERSC | “GERSC is a new, subcutaneously (SC) administered polymeric formulation of Granisetron that was developed to provide slow, controlled, and sustained release of granisetron to...” NCT04085393 ↗ |
| Known as | GNS | “Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers” NCT02563951 ↗ |
| Known as | Granisetron (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | GRANISETRON EXTENDED RELEASE INJECTION | “GRANISETRON EXTENDED RELEASE INJECTION (GERSC)” NCT04085393 ↗ |
| Known as | Granisetron hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | granisetron hydrochloride | “Kytril® (granisetron hydrochloride)” NCT00873197 ↗ |
| Known as | Granisetron Hydrochloride Nasal Spray | “Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers” NCT02563951 ↗ |
| Known as | Granisetron hydrochloride preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granisetron TDS | “Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)” NCT00890565 ↗ |
| Known as | Granisetron Transdermal Delivery System | “The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV...” NCT01662687 ↗ |
| Known as | Granisetron Transdermal System | “The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 |
| Known as | Granisol | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granisteron hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granitryl | “1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .” NCT06502067 ↗1“Granisetron (Granitryl 1 mg/ml, ampules, EGYPHARMA, Egypt)” NCT07401745 ↗ |
| Known as | GTDS | “The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV...” NCT01662687 ↗1“OBJECTIVE: To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing” PMID 39026165 ↗ Jul 2024 |
| Known as | GTS | “The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 |
| Known as | intravenous graniseton | “Drug: intravenous graniseton” NCT05474001 ↗ |
| Known as | Kytril | “Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775...” NCT03333824 ↗1“The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations” NCT00502437 ↗ |
| Known as | LY-278584 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Neoset | “Patients in Group G received 3 mg granisetron (Neoset, Deva, Istanbul)” NCT06454825 ↗ |
| Known as | NSC-759839 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Sancuso | “Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV)” NCT01659775 ↗4“Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)” NCT00890565 ↗ “Transdermal Granisetron (Sancuso® Patch)” NCT01596426 ↗ “Transdermal Granisetron (Sancuso® Patch)” NCT01596413 ↗ |
| Known as | SP-01 | “A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting” NCT01937156 ↗ |
| Known as | Staccato Granisetron | “A single oral dose of 0.5 mg AZ-010 (Staccato Granisetron) administered to 8 subjects” NCT04200092 ↗1“Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ |
| Known as | SUSTOL | “SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV)” NCT05434663 ↗ |
| Action | Inhibit | “Patients receive their scheduled chemotherapy regimen containing doxorubicin and their scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron,...” NCT00020657 ↗1“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL289469 ↗ |
| Modality | Other / unclassified | “Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug” NCT04912271 ↗ |
| Route | Oral | “Arm III: Patients receive oral granisetron hydrochloride once daily for 14 days.” NCT00004219 ↗ |
| Target | HTR3A | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL289469 ↗ |